Healthcare Service Provider
See all in Find stocks →P/E
50.4×
ROCE
23.8%
Op. margin
17.4%
Sales growth 3Y
17.2%
Profit growth 3Y
27.5%
Share price 1Y
−0.1%
Companies
| Company | Market cap | P/E | ROCE | Op. margin | Sales growth 3Y | Share price 1Y |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | ₹32K Cr | 58.7× | 29.2% | 23.0% | 11.1% | +17.1% |
| Vijaya Diagnostic Centre | ₹15K Cr | 79.4× | 30.1% | 31.0% | 21.0% | +41.8% |
| Metropolis Healthcare | ₹11K Cr | 56.2× | 19.5% | 16.8% | 12.8% | +8.9% |
| Thyrocare Technologies | ₹7K Cr | 50.4× | 37.3% | 25.6% | 16.3% | −0.9% |
| Nephrocare Health Services | ₹6K Cr | 80.2× | — | 14.0% | 31.7% | — |
| Suraksha Diagnostic | ₹2K Cr | 46.0× | 25.4% | 18.1% | 17.7% | −0.1% |
| Krsnaa Diagnostics | ₹2K Cr | 16.8× | 11.1% | 14.9% | 16.6% | −36.2% |
| 3B Blackbio Dx | ₹1K Cr | 20.0× | 22.3% | 30.9% | 31.9% | — |
| Health X Platform | ₹919.307 Cr | — | -3.7% | -5.0% | 8.3% | −1.3% |
| Gaudium IVF and Women Health | ₹770.521 Cr | 31.5× | — | 8.8% | 33.1% | — |
Largest companies first. See every company in Find stocks →
Medians from the latest consolidated results (2026-11-01); share price change over the last year.